LISATA THERAP.INC.DL-001 Market Cap ($8.06 Million)
Market Cap & Net Worth: LISATA THERAP.INC.DL-001 (8NE)
LISATA THERAP.INC.DL-001 market cap. LISATA THERAP.INC.DL-001 (F:8NE) has a market capitalization of $8.06 Million (€6.90 Million) as of November 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #27476 globally and #2355 in its home market, demonstrating a -7.51% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LISATA THERAP.INC.DL-001's stock price €0.80 by its total outstanding shares 9010937 (9.01 Million). Also see LISATA THERAP.INC.DL-001 operating cash flow efficiency for how efficiently the company converts equity into cash flow.
LISATA THERAP.INC.DL-001 Market Cap History (2015–2026)
LISATA THERAP.INC.DL-001 market cap history from 2015 to 2026. Data shows change from $1.56 Billion to $8.43 Million (-38.72% CAGR). Check LISATA THERAP.INC.DL-001 (8NE) stock price for real-time trading data and today's change.
LISATA THERAP.INC.DL-001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LISATA THERAP.INC.DL-001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of LISATA THERAP.INC.DL-001 to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
97.29x
LISATA THERAP.INC.DL-001's market cap is 97.29 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $29.50 Million | $1.00 Million | -$19.98 Million | 29.50x | N/A |
| 2025 | $16.54 Million | $170.00K | -$16.59 Million | 97.29x | N/A |
Competitor Companies of 8NE by Market Capitalization
Companies near LISATA THERAP.INC.DL-001 in the global market cap rankings as of November 3, 2026. Also see 8NE asset base for a full breakdown of the balance sheet.
Key companies related to LISATA THERAP.INC.DL-001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of LISATA THERAP.INC.DL-001 (2015–2026)
Market capitalization of LISATA THERAP.INC.DL-001 from 2015 to today. Between 2015 and today, LISATA THERAP.INC.DL-001's market cap moved from $1.56 Billion to $ 8.43 Million, with a yearly change of -38.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €8.43 Million | -49.04% |
| 2025 | €16.54 Million | -43.93% |
| 2024 | €29.50 Million | +12.90% |
| 2023 | €26.13 Million | +14.81% |
| 2022 | €22.76 Million | -80.00% |
| 2021 | €113.78 Million | -38.46% |
| 2020 | €184.88 Million | -40.61% |
| 2019 | €311.30 Million | -34.11% |
| 2018 | €472.48 Million | +4.36% |
| 2017 | €452.73 Million | +11.00% |
| 2016 | €407.85 Million | -73.85% |
| 2015 | €1.56 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 2nd, 2026 the market cap of LISATA THERAP.INC.DL-001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.06 Million USD |
| MoneyControl | $8.06 Million USD |
| MarketWatch | $8.06 Million USD |
| marketcap.company | $8.06 Million USD |
| Reuters | $8.06 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LISATA THERAP.INC.DL-001
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more